Jones H B, Harbottle S J, Bowdler A L
Experimental Morphology, Safety of Medicines Department, Zeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom.
Arch Toxicol. 1994;69(1):52-8. doi: 10.1007/s002040050137.
A previous study demonstrated that administration of phenobarbitone to male AP Wistar rats for up to 7 days caused alterations in labelling indices (LIs) in several different tissues (including a reduction of the endocrine pancreas population LI) as determined by immunohistochemical visualisation of 5-bromo-2'-deoxyuridine (BrdU) incorporation into S-phase nuclei. The primary objective of this study was to determine whether treatment with phenorbarbitone influenced the replicative states of specific cohorts of the islet (of Langerhans) cell population or generated a uniform depression of LI. Quantitation of the LIs of individual islet cell cohorts was achieved by utilisation of a dual immunohistochemical staining method for BrdU and islet hormones (insulin, glucagon and somatostatin) using a sequential peroxidase anti-peroxidase (PAP)/alkaline phosphatase anti-alkaline phosphatase (APAAP) method employing diaminobenzidine and New Fuchsin chromogens, respectively. We observed reductions, increases and no change in LIs of insulin-, glucagon- and somatostatin-positive cells, respectively. We conclude that the decreased LI of the insulin-positive cohort was not countered entirely by the LI increase in the glucagon-positive cohort due to the larger size of the former. Furthermore, the effects of phenobarbitone treatment are not manifested generally in the islet cell population but in the insulin- and glucagon-positive cohorts only. The causation of these effects is unknown but is likely to be due to enhanced carbohydrate and hormone metabolism. We believe that the visualisation and quantitation of replicating cells in specific hormone-positive cohorts of the islet cell population provide opportunities for understanding the influence of xenobiotics and disease processes on pancreatic function.
先前的一项研究表明,给雄性AP Wistar大鼠服用苯巴比妥长达7天,会导致几种不同组织的标记指数(LIs)发生改变(包括内分泌胰腺群体标记指数降低),这是通过免疫组织化学可视化5-溴-2'-脱氧尿苷(BrdU)掺入S期细胞核来确定的。本研究的主要目的是确定苯巴比妥治疗是否会影响胰岛(朗格汉斯岛)细胞群体中特定亚群的复制状态,或者是否会导致标记指数的普遍降低。通过使用一种双重免疫组织化学染色方法,即分别使用二氨基联苯胺和新番红作为显色剂,采用顺序过氧化物酶抗过氧化物酶(PAP)/碱性磷酸酶抗碱性磷酸酶(APAAP)方法,对BrdU和胰岛激素(胰岛素、胰高血糖素和生长抑素)进行双重免疫组织化学染色,实现了对单个胰岛细胞亚群标记指数的定量。我们观察到胰岛素阳性、胰高血糖素阳性和生长抑素阳性细胞的标记指数分别降低、升高和无变化情况。我们得出结论,由于胰岛素阳性亚群的规模较大,胰高血糖素阳性亚群标记指数的升高并不能完全抵消胰岛素阳性亚群标记指数的降低。此外,苯巴比妥治疗的影响并非普遍表现在胰岛细胞群体中,而仅表现在胰岛素阳性和胰高血糖素阳性亚群中。这些影响的原因尚不清楚,但可能是由于碳水化合物和激素代谢增强所致。我们认为,对胰岛细胞群体中特定激素阳性亚群中复制细胞的可视化和定量分析,为理解外源性物质和疾病过程对胰腺功能的影响提供了机会。